MX2020002568A - Composiciones y procesos para el suministro, la expresión y la modulación dirigidos de ácidos ribonucleicos de codificación en tejido. - Google Patents
Composiciones y procesos para el suministro, la expresión y la modulación dirigidos de ácidos ribonucleicos de codificación en tejido.Info
- Publication number
- MX2020002568A MX2020002568A MX2020002568A MX2020002568A MX2020002568A MX 2020002568 A MX2020002568 A MX 2020002568A MX 2020002568 A MX2020002568 A MX 2020002568A MX 2020002568 A MX2020002568 A MX 2020002568A MX 2020002568 A MX2020002568 A MX 2020002568A
- Authority
- MX
- Mexico
- Prior art keywords
- sequence
- composition
- binding site
- expression
- modulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 229920002477 rna polymer Polymers 0.000 title 1
- 108091070501 miRNA Proteins 0.000 abstract 4
- 239000002679 microRNA Substances 0.000 abstract 4
- 108091023045 Untranslated Region Proteins 0.000 abstract 3
- 108091026890 Coding region Proteins 0.000 abstract 2
- 108020004999 messenger RNA Proteins 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 238000013459 approach Methods 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 230000000174 oncolytic effect Effects 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1714430.4A GB201714430D0 (en) | 2017-09-07 | 2017-09-07 | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| US201862632056P | 2018-02-19 | 2018-02-19 | |
| PCT/US2018/049772 WO2019051100A1 (en) | 2017-09-07 | 2018-09-06 | COMPOSITIONS AND METHODS FOR TARGETED CODING ADMINISTRATION, EXPRESSION AND MODULATION OF RIBONUCLEIC ACIDS IN TISSUE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002568A true MX2020002568A (es) | 2020-09-18 |
Family
ID=60117350
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002568A MX2020002568A (es) | 2017-09-07 | 2018-09-06 | Composiciones y procesos para el suministro, la expresión y la modulación dirigidos de ácidos ribonucleicos de codificación en tejido. |
| MX2020008606A MX2020008606A (es) | 2017-09-07 | 2019-02-19 | Composiciones y metodos para la expresion y modulacion de proteccion de organos de acidos ribonucleicos codificadores. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008606A MX2020008606A (es) | 2017-09-07 | 2019-02-19 | Composiciones y metodos para la expresion y modulacion de proteccion de organos de acidos ribonucleicos codificadores. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11359212B2 (enExample) |
| EP (2) | EP4218770A3 (enExample) |
| JP (4) | JP2020533411A (enExample) |
| KR (1) | KR102741572B1 (enExample) |
| CN (1) | CN111212650A (enExample) |
| AU (1) | AU2018328289B2 (enExample) |
| CA (1) | CA3074293A1 (enExample) |
| ES (1) | ES2942890T3 (enExample) |
| GB (1) | GB201714430D0 (enExample) |
| MX (2) | MX2020002568A (enExample) |
| PL (1) | PL3678673T3 (enExample) |
| PT (1) | PT3678673T (enExample) |
| RU (1) | RU2020112990A (enExample) |
| WO (1) | WO2019051100A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020530454A (ja) | 2017-08-07 | 2020-10-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 安全な細胞治療薬を生成するためのプラットフォーム |
| GB201714430D0 (en) | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| IL295724A (en) * | 2020-02-21 | 2022-10-01 | Combined Therapeutics Inc | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids |
| WO2022035621A1 (en) | 2020-07-31 | 2022-02-17 | Combined Therapeutics, Inc. | Compositions and methods for improved vaccination |
| WO2022233880A1 (en) | 2021-05-03 | 2022-11-10 | Curevac Ag | Improved nucleic acid sequence for cell type specific expression |
| CN113444744A (zh) * | 2021-06-28 | 2021-09-28 | 北京鼎成肽源生物技术有限公司 | 一种用于基因编辑NK细胞的mRNA模板及构建方法、mRNA的体外转录方法和应用 |
| CN114107347B (zh) * | 2021-11-24 | 2022-10-28 | 中国人民解放军空军军医大学 | 一种基于具有按需抗炎功能、装载炎症响应型mRNA的工程化外泌体及其构建方法和应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004529607A (ja) * | 2000-09-15 | 2004-09-30 | キュラジェン コーポレイション | ヒトポリヌクレオチドおよびそれによってコードされるポリペプチド |
| EP2140879A1 (en) * | 2001-05-09 | 2010-01-06 | M'S Science Corporation | Composition and method for treating cancer using herpes virus |
| SG179291A1 (en) * | 2003-06-18 | 2012-04-27 | Genelux Corp | Modified recombinant vaccinia viruses and other microorganisms, uses thereof |
| EP1648914A4 (en) | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA |
| WO2009012263A2 (en) | 2007-07-18 | 2009-01-22 | The Trustees Of Columbia University In The City Of New York | Tissue-specific micrornas and compositions and uses thereof |
| MX353900B (es) | 2008-11-07 | 2018-02-01 | Massachusetts Inst Technology | Lipidoides de aminoalcohol y usos de los mismos. |
| WO2011101912A1 (ja) * | 2010-02-19 | 2011-08-25 | 国立大学法人東京大学 | 組み換えヘルペスウイルス及び組換えヘルペスウイルスを含む医薬組成物 |
| EP2763701B1 (en) * | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| KR20140102759A (ko) * | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| CA2863799C (en) | 2012-02-22 | 2020-09-01 | Matthew J. FRIGAULT | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| CA2892529C (en) * | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| WO2015058069A1 (en) * | 2013-10-18 | 2015-04-23 | Moderna Therapeutics, Inc. | Compositions and methods for tolerizing cellular systems |
| JP6588024B2 (ja) * | 2013-10-28 | 2019-10-09 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | 腫瘍溶解性ｈｓｖベクター |
| CN105848674A (zh) * | 2013-11-11 | 2016-08-10 | 阿尔莫生物科技股份有限公司 | 将白细胞介素-10用于治疗疾病和病症的方法 |
| US20170202979A1 (en) * | 2014-07-17 | 2017-07-20 | Modernatx, Inc. | Terminal modifications of polynucleotides |
| US11351271B2 (en) * | 2014-09-08 | 2022-06-07 | Massachusetts Institute Of Technology | RNA-based logic circuits with RNA binding proteins, aptamers and small molecules |
| WO2016049512A1 (en) * | 2014-09-26 | 2016-03-31 | University Of Massachusetts | Rna-modulating agents |
| WO2016100812A1 (en) * | 2014-12-19 | 2016-06-23 | Moderna Therapeutics, Inc. | Terminal modifications of polynucleotides |
| WO2017013419A1 (en) * | 2015-07-20 | 2017-01-26 | Virttu Biologics Limited | Use of oncolytic herpes simplex virus, alone or in combination with immune checkpoint inhibitor, in the treatment of cancer |
| CA3001003A1 (en) * | 2015-10-05 | 2017-04-13 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| CN108474003A (zh) * | 2015-11-20 | 2018-08-31 | 俄勒冈健康与科学大学 | 包含微小rna识别元件的cmv载体 |
| EP4089166A1 (en) * | 2016-01-27 | 2022-11-16 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| RU2765874C2 (ru) | 2016-10-26 | 2022-02-04 | МОДЕРНАТиЭкс, ИНК. | Матричные рибонуклеиновые кислоты для усиления иммунных ответов и способы их применения |
| EP3558356A2 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Mers coronavirus vaccine |
| GB201714430D0 (en) | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| EP4008333A1 (en) | 2018-02-19 | 2022-06-08 | Combined Therapeutics, Inc. | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids |
| IL295724A (en) * | 2020-02-21 | 2022-10-01 | Combined Therapeutics Inc | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids |
-
2017
- 2017-09-07 GB GBGB1714430.4A patent/GB201714430D0/en not_active Ceased
-
2018
- 2018-09-06 ES ES18792572T patent/ES2942890T3/es active Active
- 2018-09-06 EP EP23153161.7A patent/EP4218770A3/en active Pending
- 2018-09-06 MX MX2020002568A patent/MX2020002568A/es unknown
- 2018-09-06 CA CA3074293A patent/CA3074293A1/en active Pending
- 2018-09-06 JP JP2020536493A patent/JP2020533411A/ja active Pending
- 2018-09-06 EP EP18792572.2A patent/EP3678673B1/en active Active
- 2018-09-06 RU RU2020112990A patent/RU2020112990A/ru unknown
- 2018-09-06 WO PCT/US2018/049772 patent/WO2019051100A1/en not_active Ceased
- 2018-09-06 KR KR1020207009937A patent/KR102741572B1/ko active Active
- 2018-09-06 PT PT187925722T patent/PT3678673T/pt unknown
- 2018-09-06 PL PL18792572.2T patent/PL3678673T3/pl unknown
- 2018-09-06 CN CN201880066146.2A patent/CN111212650A/zh active Pending
- 2018-09-06 AU AU2018328289A patent/AU2018328289B2/en active Active
-
2019
- 2019-02-19 MX MX2020008606A patent/MX2020008606A/es unknown
-
2020
- 2020-03-06 US US16/811,504 patent/US11359212B2/en active Active
-
2022
- 2022-03-28 US US17/706,522 patent/US12195746B2/en active Active
-
2023
- 2023-08-03 JP JP2023127023A patent/JP2023159160A/ja active Pending
-
2024
- 2024-02-02 JP JP2024015220A patent/JP2024059656A/ja active Pending
- 2024-05-16 JP JP2024080380A patent/JP2024122983A/ja active Pending
- 2024-12-17 US US18/984,898 patent/US20250129383A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11359212B2 (en) | 2022-06-14 |
| PT3678673T (pt) | 2023-04-24 |
| US20220220506A1 (en) | 2022-07-14 |
| GB201714430D0 (en) | 2017-10-25 |
| AU2018328289A1 (en) | 2020-03-19 |
| KR20200104282A (ko) | 2020-09-03 |
| PL3678673T3 (pl) | 2023-07-10 |
| EP3678673B1 (en) | 2023-01-25 |
| JP2024122983A (ja) | 2024-09-10 |
| EP4218770A2 (en) | 2023-08-02 |
| RU2020112990A3 (enExample) | 2022-03-05 |
| JP2020533411A (ja) | 2020-11-19 |
| US12195746B2 (en) | 2025-01-14 |
| US20250129383A1 (en) | 2025-04-24 |
| JP2023159160A (ja) | 2023-10-31 |
| RU2020112990A (ru) | 2021-10-07 |
| MX2020008606A (es) | 2020-09-21 |
| US20200255863A1 (en) | 2020-08-13 |
| CA3074293A1 (en) | 2019-03-14 |
| KR102741572B1 (ko) | 2024-12-10 |
| RU2020130763A3 (enExample) | 2022-03-22 |
| EP3678673A1 (en) | 2020-07-15 |
| JP2024059656A (ja) | 2024-05-01 |
| RU2020130763A (ru) | 2022-03-21 |
| ES2942890T3 (es) | 2023-06-07 |
| EP4218770A3 (en) | 2023-08-09 |
| CN111212650A (zh) | 2020-05-29 |
| AU2018328289B2 (en) | 2025-07-10 |
| WO2019051100A1 (en) | 2019-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020002568A (es) | Composiciones y procesos para el suministro, la expresión y la modulación dirigidos de ácidos ribonucleicos de codificación en tejido. | |
| Yang et al. | Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis | |
| SA522432139B1 (ar) | بروتينات ربط متعددة الخصوصية لمعالجة السرطان | |
| Yeom et al. | Supramolecular hydrogels for long‐term bioengineered stem cell therapy | |
| ZA202002094B (en) | Trispecific proteins and methods of use | |
| SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
| MX373926B (es) | Metodos para tratar cancer y estados no neoplasicos. | |
| RU2017126610A (ru) | Терапевтические композиции и способы против злокачественных опухолей с молекулами рнки, направленными против hsp47 | |
| BR112014008932A2 (pt) | bicamadas lipídicas suportadas em nanopartículas porosas (protocélulas) para administração direcionada, incluindo a administração transdérmica de uma carga e métodos associados | |
| WO2018140920A8 (en) | Compositions and methods for inhibition of factor xii gene expression | |
| NZ739133A (en) | Cellular targeted active ingredient delivery system | |
| WO2011119628A3 (en) | Compositions and methods for self-adjuvanting vaccines against microbes and tumors | |
| Su et al. | PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth | |
| BR112017027985A2 (pt) | peptídeos terapêuticos e métodos de uso dos mesmos | |
| MX2021001423A (es) | Vectores virales encapsulados en polimero para terapia genica. | |
| ZA202207211B (en) | Peptide docking vehicle for targeted nucleic acid delivery | |
| WO2021081457A3 (en) | Methods and agents for enhancing t cell therapies | |
| SG10201807554QA (en) | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment | |
| MX2021014867A (es) | Metodos y composiciones para el tratamiento del cancer con adyuvantes dirigidos al cancer. | |
| MX2020011290A (es) | Ligandos dirigidos a la integrina y sus usos. | |
| CN104610435B (zh) | 一种能靶向抑制erk信号通路的抗肿瘤多肽及其应用 | |
| WO2009099959A3 (en) | Tumor cell expression of neuropilin as a target for cancer therapy | |
| WO2013133873A3 (en) | Pharmaceutical compositions of sodium ion and calcium ion and methods for treating cancer, tumor and non-malignancy | |
| CN101168742A (zh) | 一种溶癌病毒及其制备方法 | |
| WAKABAYASHI et al. | Gene therapy of central nervous system tumors |